Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Robak, Tadeusz; Burger, Jan A; Tedeschi, Alessandra; Barr, Paul M; Owen, Carolyn; Bairey, Osnat; Hillmen, Peter; Simpson, David; Grosicki, Sebastian; Devereux, Stephen; McCarthy, Helen; Coutre, Steven E; Quach, Hang; Gaidano, Gianluca; Maslyak, Zvenyslava; Stevens, Don A; Moreno, Carol; Gill, Devinder S; Flinn, Ian W; Gribben, John G; Mokatrin, Ahmad; Cheng, Mei; Styles, Lori; James, Danelle F; Kipps, Thomas J; Ghia, Paolo.
Am J Hematol
; 93(11): 1402-1410, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30129285
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.